Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.37 |
| ▸ | CDC25B | P30305 | 5/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | TACR2 | P21452 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24256154 | 1.00 | HTR1A (0.43) | HTR1ABCHEACHENT5EMAPK1 | |
| SCHEMBL26900837 | 0.87 | BCHE (0.43) | HTR1ABCHEACHENT5ECA1 | |
| SCHEMBL26900838 | 0.87 | BCHE (0.43) | HTR1ABCHEACHENT5ECA1 | |
| SCHEMBL24256520 | 0.87 | HTR1A (0.41) | HTR1ABCHEACHENT5ECA1 | |
| SCHEMBL26900842 | 0.87 | HTR1A (0.41) | HTR1ABCHEACHENT5ECA1 | |
| SCHEMBL24256152 | 0.84 | HTR1A (0.38) | HTR1ABCHEACHENT5ECA1 | |
| SCHEMBL26900860 | 0.84 | HTR1A (0.38) | HTR1ABCHEACHENT5ECA1 | |
| SCHEMBL24256721 | 0.83 | BCHE (0.44) | HTR1ABCHEACHENT5ECA1 | |
| SCHEMBL26900879 | 0.83 | BCHE (0.44) | HTR1ABCHEACHENT5ECA1 | |
| SCHEMBL26900849 | 0.83 | BCHE (0.39) | HTR1ABCHEACHENT5ECA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | HTR1A 3660/4885BCHE 2461/4885ACHE 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.